Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. International guidelines on menopausal hormone therapy (MHT) do not specify on progestogen type, dosage, route of application and duration of safe use. At the same time, the debate on bioidentical hormones including micronized progesterone increases. Based on a systematic literature review on micronized progesterone for endometrial protection, an international expert panel's recommendations on MHT containing micronized progesterone are as follows: (1) oral micronized progesterone provides endometrial protection if applied sequentially for 12-14 days/month at 200 mg/day for up to 5 years; (2) vaginal micronized progesterone may provide endometrial protection if applied sequentially for at least 10 days/month at 4% (45 mg/day) or every other day at 100 mg/day for up to 3-5 years (off-label use); (3) transdermal micronized progesterone does not provide endometrial protection.
Introduction
The steroid hormone progesterone plays a key role in female reproduction 1 . For therapeutic reasons, micronized progesterone (MP) can be used for endometrial protection when estrogens are applied in menopausal women with an intact uterus 2 . However, there is considerable debate about whether and at which dosage MP provides effective endometrial protection if applied orally, vaginally, or transdermally 3 . To discuss various topics on MP, an international expert meeting of gynecological endocrinologists from the German-speaking countries Austria, Germany and Switzerland was held in April 2015 aiming to provide scientifically proven statements on MP treatment in peri-and postmenopausal women, based on a systematic literature search and discussion of the results. Endometrial protection by MP will be the first topic of the planned series.
Material and methods
A systematic literature search was performed using databases (Medline (Pubmed), Biosis (Medpilot) and Cochrane (Cochrane Library)), clinical trial registers (www.clinicaltrialsregister.eu, www.clinicaltrial.gov, http://apps.who.int/trialsearch/), and the experts' own literature collection). Searches were performed using a combination of keywords and Mesh-terms and text words related to ''(post-/peri)menopause'' or ''hormone/estrogen replacement therapy'', ''progesterone'', ''endometrial cancer/neoplasm/hyperplasia'' or ''endometrial biopsy'' or ''endometrial proliferation/atrophy''. Estrogen dosages were classified as high-dose, standard-dose, low-dose and ultralow-dose by the expert group according to the definition of the International Menopause Society 4 . No time restriction was applied. The selection process involved a pre-selection via title and/or abstracts by two independent reviewers (A.L., B.H.) based on the PICO criteria (Table 1) . Discrepancies between the reviewers were discussed and resolved by consensus. Included abstracts were ordered as full articles. The selection process for full articles was performed accordingly. Meta-analyses and systematic reviews were searched for secondary literature. The final eligibility assessment and evaluation of the studies' quality were performed by the expert group (P.S., J.N., L.W.)
Endometrial thickness
Endometrial thickness measured by TVUS was assessed in postmenopausal women in one 3-year, placebo-controlled, randomized, controlled trial (RCT) (n ¼ 167) 21 and two 1-year RCTs (n ¼ 100) with head-to-head comparisons 5, 6 . Participants received continuous, transdermal estradiol (E2) (25 21 -50 5, 6 lg/ day) which was sequentially combined with either different oral progestogens (medroxyprogesterone acetate (MPA), nomegestrol acetate (NOMAC), dydrogesterone (DYD), MP) 6 , MP applied orally or vaginally at different dosages (100 or 200 mg/day) 5 or oral MP 100 mg/day for 2 weeks every 6 months (extended cycle) 21 . In those studies with head-tohead comparisons, there were no significant group differences for endometrial thickness at baseline and after 12 cycles 5, 6 . When comparing the baseline endometrial thickness with that at study closure, there was either no change (extended cycle regimen at oral MP 100 mg/day 21 , sequential regimen at vaginal MP 200 mg/day 5 ), or a significant increase 5, 6 . Another two small, non-controlled studies using either oral MP 200-300 mg/day for 10 days per month 16 or 100 mg/day for 23 days per month 10 reported no change 10 or an endometrial thickness of less than 2 mm after 1 year 16 . The method of endometrial thickness assessment was described by two authors only 5, 6 using the maximal thickness of the endometrium in the longitudinal plane of the uterus.
Endometrial histology
Endometrial biopsies were performed in 17 studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] of which eight were RCTs 12, 13, 15, 17, 18, 21, 22, 24 including two placebo-controlled RCTs 15, 21 . Endometrial biopsy procedure was described by all but six authors 12, 13, 16, 20, 21, 25 . The majority either used a pipelle de Cornier 14, 15, 18, 22, 24, 26 or Novak's curette 14, 15, 18, 22, 26 . Others used a needle aspiration (pistolet method) 23 , vabra suction curettage 10, 11, 15, 19 or performed a conventional dilatation and curettage 17, 19 . A hysteroscopy was only performed in one study if no tissue was obtained 20 . The sample size ranged from 17 16 to 596 15 women being postmenopausal in all but one study 16 . Treatment duration ranged from 4 months 12,24 to 5 years 20 . Conjugated equine estrogens (CEE) were the most common estrogen component of menopausal hormone therapy (MHT) while others used 17b-estradiol. Estrogen dosage was either high-dose 14, 17, 19 , standard-dose [10] [11] [12] [13] [14] [15] [16] 18, 20, [22] [23] [24] [25] [26] , low-dose 25 or ultra-low-dose 21 . Estrogens were applied either orally or transdermally. MP was examined either at different dosages ranging from 50 mg/ day 12 , 100 mg/day [10] [11] [12] 14, 19, 21, [24] [25] [26] , 200 mg/day 9, 13, [15] [16] [17] [18] [19] [20] 22, 23 , 300 mg/day 14, 16, 17, 19, 24 to 400 mg/day 24 or compared to other progestins (intrauterine levonorgestrel (LNG) 23 , oral chlormadinone acetate (CMA) 18, 22 , oral MPA 15, 16 ). The regimen of combined MHT differed, ranging from continuously combined MHT (28 days per cycle/whole month), intermittently combined MHT (25 days per cycle followed by a 5-day hormone break) to sequentially combined MHT (continuous estrogen therapy combined with a progestogen for 10-14 days per cycle/month). Endometrial biopsies were taken at the end of all trials and also at baseline in all but four studies 14, [19] [20] [21] . Evaluation of tissue biopsies differed tremendously. Histomorphology was the most common method used to differentiate between proliferative, secretory and atrophic endometrium [10] [11] [12] [13] [14] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] , and, if applicable, normal, hyperplastic and cancerous endometrium 10, 11, 15, [19] [20] [21] 24 . Treatment success may be defined as yielding an atrophic, inactive or secretory endometrium whereas treatment failure corresponds to a proliferative endometrium response or hyperplasia 22 . In addition, some investigators assessed histomorphometry 17 , mitotic count 14, 26 , mitotic index 20 , DNA synthesis 26 , proliferation index (MIB) 24 , or used transmission electron microscopy and biochemistry markers 19 . Treatment success by oral MP was reported by 11 studies [10] [11] [12] [13] [14] 16, 18, 19, 22, 24, 25 . Seven studies used a continuous 11, 12, 16 or intermittent 10, 14, 24, 25 , and four studies a sequential 13, 18, 19, 22 MHT regimen. Treatment success was achieved by MP 100-400 mg/day if an intermittent MHT regimen was applied 10, 12, 14, 16, 24, 25 . However, absolute numbers ranged between 3.8% (MP 100 mg/day) 14 and 100% (MP 200 mg/ day) 12 for atrophic, and between 0% (MP 200 mg/day) 12 and 64% (MP 400 mg/day) 24 for secretory endometrium, while a proliferative or mildly active endometrium was found in 0% (MP 100-200 mg/day) 12 to 23.1% (MP 100 mg/day) 14 . Accordingly, treatment success was achieved with a sequential MHT regimen if MP 200-300 mg/day was applied 13, 18, 19, 22 . In detail, the endometrium was found to be atrophic in 20.8% 22 to 56% (MP 200 mg/day) 13 , secretory in 62.5% (MP 200 mg/day) 18, 22 to 83% (MP 300 mg/day) 19 and proliferative in 8.3% 22 to 31% 13 (MP 200 mg/day). In contrast, other studies found an insufficient endometrial transformation if oral MP was applied intermittently or continuously at 100-200 mg/ day 23, 26 or sequentially at 100-300 mg/day 17, 19, 20 . The heterogeneity of results and their interpretation by the authors may be attributed to the differences between cohorts, study designs, endometrium evaluation techniques, thresholds for treatment success, and also to the lack of sufficient correlation between histomorphology and endometrial safety. For example, the lack of complete glandular and stromal progestational changes has not been found to be associated with any detectable impairment in antiproliferative effects. Thus, the inhibition of endometrial proliferation may be dissociated from secretory maturational changes 20 and therefore a complete secretory maturation may not be required for the prevention of hyperplasia 14 . Jondet and colleagues even stated that the histological classification using proliferative and secretory items does not represent the physiological aspects seen in normal cycles but rather indicates whether the pathologist is able to detect any progestogenic action 18 . That said, it might be more revealing to assess the prevalence of endometrial hyperplasia in endometrium biopsies. Two small (n ¼ 40-50) 10, 11, 19 , one short (4 months) 24 and one study using an extended cycle regimen (MP every 6 months) 21 reported one case with (simple) hyperplasia each 21, 24 , or an 1% increase of the prevalence of simple hyperplasia 10, 11 , respectively, using a sequentially 19 or quasi continuously combined MHT 7, 8 with MP 100 mg/day. In contrast, the study with the longest intervention (5 years) did not find any case of endometrial hyperplasia or carcinoma in women having applied an 17b-estradiol (E2) patch sequentially combined with MP 200 mg/day 20 . However, there were only 53 endometrial biopsies with adequate tissue in 153 women completing the study. Thus, the largest study to date (n ¼ 596) is the placebo-controlled RCT Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) with a 3-year intervention phase using a sequentially combined MHT with MP 200 mg/day among others 15 . In this study, all combined MHT regimens were effective in preventing hyperplasia comparable to placebo.
Endometrial cancer incidence
Endometrial cancer incidence in respect to MHT containing oral MP was assessed by two prospective cohort studies, the European Prospective Investigation into Cancer and Nutrition study (EPIC) 7 and the E3N 8 , with E3N being the French cohort of EPIC. The sample size ranged from 65 630 8 to 115 474 7 postmenopausal women; the mean follow-up was 9.0 7 and 10.8 8 years, respectively. A self-administered questionnaire containing information on MHT use was sent to participants once at baseline 7 or every 2-3 years 8 . Within the E3N cohort, a woman who successively took different types of MHT simultaneously contributed to each category. The study designs did not include gynecological examinations. Information on the type of estrogen-progestogen therapy (EPT) regimen (sequential or continuous) was available for 61% of EPT users in EPIC 7 and missing in E3N 8 . Data on adherence to medication, prescription and diagnostic bias were not assessed. While E3N only included EPT users with oral MP, EPIC did not differentiate between oral, vaginal and transdermal MP application. MP dosage was not reported in both, EPIC and E3N. Mean duration of EPT use was 2.5 years in EPIC (irrespective of progestogen constituent) 7 , and 4.2 years in users of MPcontaining EPT in E3N 8 . During follow-up, 601 7 and 301 8 incident endometrial cancers were reported (e.g. self-report, population cancer registries, health insurance records). Tumor histology was reported in EPIC 7 (not in E3N) and tumor stage in E3N 8 (not in EPIC). In current users of MP-containing EPT, there were 26 endometrial cancer cases in EPIC (2231 noncases) and 54 cases in E3N (number of non-cases not given).
Current use of MP-containing EPT was associated with a significantly increased risk of endometrial cancer in both, EPIC (hazard ratio (HR) 2.42; 95% confidence interval (CI) 1.53-3.83) 7 and E3N (HR 1.96; 95% CI 1.41-2.73) 8 . The impact of treatment duration was only analyzed in E3N, showing an increased risk after more than 5 years of use but not below 8 . Endometrial cancer risk was not assessed in respect to tumor histology, specifically to hormone dependency or independency of the tumor. There is only one 4-year RCT, the Kronos Early Estrogen Prevention Study (KEEPS), comparing oral sequential MHT containing MP (200 mg/day) to placebo 9 . The incidence of endometrial cancer was assessed as an adverse event. There was no significant difference in endometrial cancer cases between MHT users (n ¼ 3) and placebo (n ¼ 0).
Vaginal application of MP
The effect of vaginal MP on the endometrium has been assessed by TVUS 5, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , endometrial biopsy 23,27-39 and endometrial cancer incidence 40 (Table 3) .
Endometrial thickness
Endometrial thickness measured by TVUS was assessed in 11 studies 5,27-36 of which four were RCTs 28, 34 . Application regimens were either sequential (7-12 days/month) 5, 27, 29 , intermittent [29] [30] [31] 33, 35, 36 or continuous 28, 32, 34 . The method of endometrial thickness assessment was described by six authors only 5, 27, 30, 32, 33, 35 . Endometrial thickness was measured at the maximal thickness of the endometrium in the longitudinal plane of the uterus, specified as double layer in some studies 27, 30, 35 . In most studies, endometrial thickness remained unchanged with a sequential (45 mg/day 29 ).
Endometrial histology
Endometrial histology was assessed by biopsy in 14 studies 23,27-39 of which five were RCTs 27, 28, 34, 38, 39 . In RCTs, vaginal MP was either compared at different dosages 28, 34, 39 to oral MPA or transdermal norethisterone sacetate (NETA) 38 or to intrauterine LNG 27 . Baseline biopsies were performed in all but four studies 32, 33, 36, 37 . In few studies, endometrial biopsies were only performed if indicated (e.g. suspect TVUS, uterine bleeding) [28] [29] [30] . Endometrial biopsy procedure was described by all authors. The majority either used a pipelle de Cornier 28, 30, 32, 34 or performed a hysteroscopy-guided targeted biopsy 29, 33, 36, 38 . Others used a Novak's curette 31, 37 , needle aspiration (pistolet method) 23, 35 , Gynoscan method 27 or vabra endometrial biopsy 39 . The sample size ranged from 9 37 to 136 29 postmenopausal women, and treatment duration from 21 days 32 to 3 years 33 . Systemic estrogens at high 37 , standard 23, 27, 29, 31, [33] [34] [35] [36] 38, 39 or low 30 dose were applied either orally 29, 39 , transdermally 23, 27, [29] [30] [31] [33] [34] [35] [36] [37] [38] or vaginally 27, 28 . Vaginal MP was applied as a capsule or as gel at different dosages ranging from 45 mg/day 29, 31, 39 , 90 mg/ day 39 , 100 mg/day 23, 27, 30, 33, [35] [36] [37] [38] to 200 mg/day 23, 32, 35 , as intramuscular injection 32 or a vaginal ring 28, 34 . Application regimens were either sequential (7-12 days/month) 27, 29, 37, 38 , intermittent 23, [29] [30] [31] 33, 35, 36, 39 or continuous 28, 34 34 , sequential or intermittent MP 100-200 mg/day 35, 38 ). Only one study reported a hyperplastic endometrium in 10% of women after 1 year without remarkable difference between groups (sequential vaginal MP cream 100 mg/day, oral MPA 10 mg/day, or transdermal NETA 0.25 mg/day) 38 .
Endometrial cancer incidence
There was only one 5-year RCT, Early versus Late Intervention Trial with Estradiol (ELITE), comparing sequential MHT containing vaginal MP (45 mg/day) to placebo 40 . The incidence of endometrial cancer was assessed as an adverse event. There was no significant difference in endometrial cancer cases between MHT users and placebo (preliminary data presented at World Congress of International Menopause Society, Cancun, 2014).
Transdermal application of MP
Five studies have been identified investigating the impact of transdermal MP on the endometrium [41] [42] [43] [44] [45] (Table 4 ). All but one study 43 were RCTs, some of which had placebo 41 or a progestin 42 as comparator. Sample size ranged from 27 44, 45 to 54 43 postmenopausal women, and study duration from 4 41 to 48 43 weeks. Estrogens were applied either orally 41, 42 or transdermally [43] [44] [45] with the dosage falling either within the highdose 44, 45 or moderate-dose 41-43 category 46 . Transdermal MP cream was applied either sequentially 41, 44, 45 or continuously 42, 43 , and the dosage ranged from 16 mg/day to 64 mg/ day 44, 45 . Transvaginal ultrasound for endometrial thickness assessment was only performed in one study 43 showing a significant increase when combining estrogens with transdermal MP cream. Endometrial biopsy was performed by all studies comparing pre-and post-treatment histology. While two studies indicated an adequate progesterone opposing effect 41, 42 , the remainder did not [43] [44] [45] . There were two cases of complex hyperplasia 43 but no endometrial cancer was found.
Discussion
Current international guidelines on MHT recommend to combine a progestogen when using estrogen therapy in peri-and postmenopausal women with an intact uterus for endometrial protection 2, [47] [48] [49] . Progestogen addition should be continuous or sequential for at least 12 days per month, as recently again pointed out by the US Endocrine Society. However, long-term endometrial safety of sequential progestogen addition may be reduced since the combination of estrogens with MP (or dydrogesterone) is associated with an increased risk of endometrial cancer if used for more than 5 years 48 . Yet, compliance, dosage and route of application of MP were not exactly known. Internationally, systemic MP is available at different dosages and routes of application. Also, indication and approval by regulatory authorities may differ from country to country. In Europe, systemic MP is available as a capsule (100 mg, 200 mg) for vaginal or oral application or as vaginal gel (8% corresponding to 90 mg).
During the last years, the debate about (compounded) bioidentical hormones has increased tremendously [50] [51] [52] . Therefore, the aim of this international expert group was to provide recommendations on the use of estrogens combined with MP in postmenopausal women in respect to endometrial safety.
The European Medicines Agency (EMA) recommends endometrial biopsies at baseline and study closure as the goldstandard method for evaluation for endometrial hyperplasia during MHT 53 . Per definition, a biopsy is evaluable if there is 'endometrial tissue sufficient for diagnosis'. Endometrial biopsies should be classified into the general classes of atrophic, proliferative, secretory, hyperplasia without atypia, hyperplasia with atypia, cancer and others. Biopsies with insufficient tissue for diagnosis may be categorized as 'atrophic endometrium' if the sonographic endometrial thickness is <5 mm. For a new MHT, combination studies of at least 12 months' duration are required. The upper limit of the 95% confidence interval of the incidence of hyperplasia or carcinoma should not exceed 2% after 1 year, requiring a sample size of 300 patients.
For oral MP, there are only three RCTs following EMA's guideline 15, 18, 22 All studies used sequential (12-14 days/ month) MP at 200 mg/day for either 1.5 18, 22 or 3 15 years. When comparing sequential CMA (10 mg/day) to sequential MP (200 mg/day), CMA provided a more complete progestogenic transformation 18, 22 . However, according to the PEPI trial, sequential MP (200 mg/day) provided adequate endometrial protection for up to 3 years, comparable to sequential or continuous MPA 15 . When further taking into account the results from KEEPS (sequential MP at 200 mg/day for 4 years) 9 and E3N 8 , the panel concluded that in postmenopausal women combining estrogens with sequential (12-14 days/month) oral MP at 200 mg/day (EMA approval) for up to 5 years provides sufficient endometrial protection. If oral MP is to be applied continuously, the initial dosage should also be 200 mg/day. This dose may be lowered off-label to 100 mg/day if an (ultra-) low-dose estrogen therapy has been chosen and amenorrhea persists. PC-RCT, Placebo-controlled, randomized controlled trial; RCT, randomized controlled trial; CEE, conjugated equine estrogen; E2; 17b-estradiol; MPA, medroxyprogesterone acetate; EPS, endometrial proliferation score; BL, baseline
For vaginal MP, no study completely followed EMA's guideline and gained approval as an adjunct to menopausal estrogen therapy. However, six studies investigated vaginal MP for at least 1 year and performed endometrial biopsies at baseline and at study closure 23, 27, 31, 35, 36, 38 .
Vaginal MP (45-200 mg/day) was applied either sequentially (7-12 days/month) 27, 38 or intermittently (25 days/ month) 23, 35, 36 . The majority of investigators concluded that sequential vaginal MP (100-200 mg/day) was insufficient to produce an adequate endometrial response 23, 35, 36, 38 . When taking into account long-term studies (3-5 years) 33, 40 , the use of sequential or intermittent vaginal MP does not seem to increase the risk of endometrial hyperplasia or cancer. However, due to the heterogeneity of studies and lack of sufficient data, the panel concluded that in postmenopausal women combining estrogens with sequential (4% corresponding to 45 mg/day on 10 days per month) or intermittent (100 mg every other day) vaginal MP for up to 3-5 years may be safe (off-label use). However, 4% MP vaginal gel is not available on the European market. Finally, the use of transdermal MP for endometrial protection cannot be recommended in postmenopausal women using estrogen therapy.
It remains difficult to interpret these data as there is a broad variety in study designs in terms of dosage per cycle, route of administration, clinical findings, sample size per protocol and even histological readings. Therefore, oral MP at 200 mg daily for at least 12 days per month is the preferred route, dose and duration for postmenopausal women with an intact uterus when using estrogen therapy for up to 5 years due to the currently available data. This conclusion seems to be applicable also for the vaginal treatment route. However, this procedure remains off-label use.
Conclusion
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. International guidelines on MHT do not specify on progestogen type, dosage, route of application and duration of safe use. Based on a systematic literature review on MP for endometrial protection, an international expert panel's recommendations on MHT containing MP are as follows: (1) oral MP provides endometrial protection if applied sequentially for 12-14 days/month at 200 mg/day for up to 5 years; (2) vaginal MP may provide endometrial protection if applied sequentially for 10 days/month at 4% (45 mg/day) or every other day at 100 mg/day for up to 3-5 years (off-label use); (3) transdermal MP does not provide endometrial protection.
